Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer

Johns, Elizabeth; Stanley, Jennifer; Toboni, Michael D.; Schwarz, Julie K.; Zhang, F.; Hagemann, Andrea R.; Fuh, Katherine C.; Thaker, Premal H.; McCourt, Carolyn K.; Mutch, David G.; Powell, Matthew A.; Khabele, Dineo; Kuroki, Lindsay M.

doi:10.1016/j.gore.2021.100808

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiation therapy has a role as localized treatment to treat ovarian cancer patients with locally recurrent vaginal or perirectal lesions. The role of this treatment modality remains unclear, though we hypothesize that these patients may be treated locally and gain long-term survival benefits [ 82 ].…”

Section: Discussionmentioning

confidence: 99%

Epithelial Ovarian Cancer: A Five Year Review

et al. 2023

View full text Add to dashboard Cite

Ovarian cancer is a malignant disease that affects thousands of patients every year. Currently, we use surgical techniques for early-stage cancer and chemotherapy treatment combinations for advanced stage cancer. Several novel therapies are currently being investigated, with gene therapy and stem cell therapy being the corner stone of this investigation. We conducted a thorough search on PubMed and gathered up-to-date information regarding epithelial ovarian cancer therapies. We present, in the current review, all novel treatments that were investigated in this field over the past five years, with a particular focus on local treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Epithelial Ovarian Cancer: A Five Year Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…However, in case of oligometastasis (especially vaginal/perirectal lesions and/or in lymph nodes) in heavily pretreated patients, intensity-modulated radiation therapy (IMRT) with additional high-dose brachytherapy could be proposed. A small retrospective study series showed that this approach is safe and provides long-term control of the irradiated region (69,70).…”

Section: Radiotherapymentioning

confidence: 99%

Recurrent High Grade Serous Ovarian Cancer Management

Luyckx¹,

Squifflet²,

Bruger³

et al. 2022

Ovarian Cancer

View full text Add to dashboard Cite

Despite an aggressive treatment strategy for high grade serous ovarian cancer (HGSOC) that incorporates cytoreduction, platinum compounds, anti-angiogenic agents, and poly (ADPribose) polymerase (PARP) inhibitors, most patients, especially those who are with stage III-IV HGSOC, will relapse. The management of recurrent HGSOC is a challenging issue faced by gyneco-oncologists and medical oncologists in clinical practice. This chapter provides an overview of the current optimal management of recurrent HGSOC. First, recurrence is classified based on the time of onset. This is followed by a discussion on the place of surgery within the treatment strategy. Finally, the role of systemic treatments (chemotherapy, targeted Note to the reader: This chapter is part of the book Ovarian Cancer (ISBN: 978-0-6453320-8-7), scheduled for publication in September 2022. The book is being published by Exon Publications,

show abstract

Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer

Cited by 2 publications

References 13 publications

Epithelial Ovarian Cancer: A Five Year Review

Epithelial Ovarian Cancer: A Five Year Review

Recurrent High Grade Serous Ovarian Cancer Management

Contact Info

Product

Resources

About